Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma; it derives from germinal center B cells. Although DLBCL harbors many genetic alterations, synergistic roles between such alterations in the development of lymphoma are largely undefined. We previously established a mouse model of lymphoma by transplanting gene-transduced germinal center B cells into mice. Here, we chose one of the frequently mutated genes in DLBCL, Card11 mutant, to explore its possible synergy with other genes, using our lymphoma model. Given that BCL6 and BCL2 expression and/or function are often deregulated in human lymphoma, we examined the possible synergy between Card11, Bcl6, and Bcl2. Germinal center B cells were induced in vitro, transduced with Card11 mutant, Bcl6, and Bcl2, and transplanted. Mice rapidly developed lymphomas, with exogenously transduced Bcl2 being dispensable. Although some mice developed lymphoma in the absence of transduced Bcl6, the absence was compensated by elevated expression of endogenous Bcl6. Additionally, the synergy between Card11 mutant and Bcl6 in the development of lymphoma was confirmed by the fact that the combination of Card11 mutant and Bcl6 caused lymphoma or death significantly earlier and with higher penetrance than Card11 mutant or Bcl6 alone. Lymphoma cells expressed interferon regulatory factor 4 and PR domain 1, indicating their differentiation toward plasmablasts, which characterize activated B cell-like DLBCL that represents a clinically aggressive subtype in humans. Thus, our mouse model provides a versatile tool for studying the synergistic roles of altered genes underlying lymphoma development.
D
iffuse large B-cell lymphoma is the most common subtype of malignant lymphoma. Genetic abnormalities are heterogeneous between DLBCL clinical samples (1) (2) (3) and a single patient harbors multiple genetic abnormalities, making it difficult to determine the genetic abnormalities specifically required for the development of lymphoma.
A number of transgenic and knockin/knockout mouse models have been generated to clarify the functional roles of the given genetic abnormalities in lymphomagenesis, (4) (5) (6) yet many remain unexplored. To explore the combinatorial effects of multiple genetic abnormalities in lymphomagenesis, such genetically modified mice need to be crossed to give rise to mice harboring the genetic abnormalities of interest in combination. However, this strategy is laborious and time-consuming. In addition, B cells of such genetically modified mice undergo SHM in genes encoding immunoglobulin as well as many other genes involved in lymphomagenesis, which provides an additional layer of difficulty in clarifying the roles of the genetic alterations of interest. In an effort to circumvent these difficulties, we previously established a mouse model of lymphoma using in vitro-induced mouse GC B cells. The GC B cells were induced in vitro, retrovirally transduced with genes or mutated genes of interest in combination, and transplanted into immunodeficient mice. (7, 8) In this model, the combinatorial effects of multiple genetic abnormalities can be assessed easily by infecting their corresponding retroviral vectors at once. Somatic hypermutation did not occur in the in vitro-induced GC B cells, therefore, the role of the genes or mutated genes of interest in the development of the lymphoma could be assessed. (7) (8) (9) Diffuse large B cell lymphomas are largely classified into two subtypes based on gene expression profile, the GCB and ABC types. (10) Genetic abnormalities that deregulate functions and/or the expression of BCL6 and BCL2 frequently occur in both subtypes of human DLBCL. Chromosomal translocations involving BCL6 that result in the constitutive expression of BCL6 in B cells are exclusively found in ABC-DLBCL. (6) Interestingly however, BCL6 is transcriptionally upregulated by somatic mutations of MEF2B (11) or evades EP300/CREBBP-mediated inactivation due to mutations in EP300/CREBBP genes, (12, 13) in some GCB-DLBCL cases. Likewise, although chromosomal translocations involving BCL2 that constitutively elevate BCL2 expression are found almost exclusively in GCB-DLBCL, gene amplification of BCL2 is observed in ABC-DLBCL. (14, 15) Moreover, BCL6 and BCL2 play critical roles in the development and maintenance of DLBCL. For example, DLBCL cell lines and BCL6-expressing patient-derived DLBCL cells often depend on BCL6 transcription activity for survival. (16) Elevated BCL2 expression promotes clonogenicity of lymphoblastoid cell lines (17) and elicits lymphoma in some, if not all, mouse lymphoma models. (18) However, enhanced activity of BCL6 or BCL2 per se is not sufficient to elicit lymphoma. Transgenic mice carrying a BCL6 (IlHABCL6 mice) (4) or BCL2 transgene under the control of the IGH genes enhancer take almost 1 year to develop lymphomas. (18, 19) Moreover, lymphomas that developed in these mice presented additional genetic abnormalities (4, 20) such as translocation of Myc. (18) Lymphoma development was significantly delayed in IlHABCL6 mice by genetic inactivation of activation-induced cytidine deaminase (21) or uracil-DNA glycosylase, (22) both of which induce SHM in cancer-related genes in addition to immunoglobulin genes. (23) Together, these findings suggest that functionally enhanced BCL6 or BCL2 requires additional genetic "hits" to elicit lymphoma.
One such candidate "hit" is a somatic mutation of CARD11. CARD11 is mutated in approximately 10% of DLBCL cases, (24) being more prevalent in ABC-DLBCL, but also occurring in GCB-DLBCL. (1, 24) Card11 mutations occur during the process of lymphoma development in a subset of IlHABCL6 mice. (20) In clinical lymphoma samples, CARD11 mutations are often accompanied by chromosomal translocations, gene amplifications, or mutations that lead to elevated activity of BCL6 or BCL2 (Fig. S1 ). (13) CARD11 is a critical component of the NFjB pathway, transmitting B-cell receptor signal to induce transcriptional activation of NF-jB target genes. CARD11 mutations occurring in DLBCL activate the NF-jB pathway even in the absence of B-cell receptor input, providing survival signals, especially in ABC-DLBCL. (24) However, mutations of CARD11 seem insufficient for the development of lymphoma in humans. Only a limited number of affected persons within a family with a germline CARD11 mutation develop lymphoma. (25) In this study, we investigated the possible synergy between Card11 mutation, Bcl6, and Bcl2, using our mouse model.
Materials and Methods
Induction of GC B cells, retroviral infection, and transplantation. Induction of GC B cells was carried out as described previously. (7, 9) Briefly, B220 + B cells were isolated from the spleens of C57BL/6N mice using antibodies for B220 (RA3-6B2; eBioscience, San Diego, CA, USA) in combination with MACS columns (Miltenyi Biotec, Bergisch Gladbach, Germany). Isolated B cells were co-cultured with X-irradiated (150 Gy) NIH3T3 cells engineered to express mouse CD40 ligand and mouse Baff (3T3/CD40L/Baff cells) in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% FCS, 5 9 10 À5 M 2-mercaptoethanol, 1 mM sodium pyruvate, 100 units/mL each of penicillin and streptomycin (Gibco), and recombinant interleukin-4 (1 ng/mL; PeproTech, Rocky Hill, NJ, USA). Four days later, the B cells were transferred onto a new feeder layer and cultured with recombinant interleukin-21 (10 ng/mL; PeproTech) for 4 days to induce GC B cells. The iGCB cells were filtered through 45-lm nylon mesh to remove feeder cells and spin-infected with the respective virus using RetroNectin (Takara Bio, Shiga, Japan) coated plates twice a day on days 3-5 after initiation of the culture. Cells were seeded back onto the feeder layer after infection. On day 8, gene-transduced iGCB cells (1 9 10 7 cells) were transplanted i.p. into sublethally irradiated (2 or 2.5 Gy) NOD-SCID mice (NOD.CB17-Prkdc; Jackson Laboratory, Bar Harbor, ME, USA) (Fig. S2) . All animal experiments were carried out according to protocols approved by the Institutional Animal Care and Use Committee at the Aichi Cancer Center (Nagoya, Japan).
Plasmids. cDNA for mouse Bcl6 was amplified from mouse spleen cDNA by PCR and cloned into MSCV-Bcl6-ires-human (h) CD4 retroviral vector. cDNA for mouse Bcl2 was cloned into MSCV-Bcl2-ires-human (h) CD8, as previously described. (26) pMX-Card11 L232LI -ires-GFP was a generous gift from Dr. Keisuke Horikawa (The Australian National University, Canberra, Australia) (27) (Fig. S3) . These plasmids were co-transfected with MCV-Ecopac plasmid (a generous gift from Dr. Richard Van Etten, Tufts-NEMC Cancer Center, Boston, MA, USA) (28) into 293T cells to produce retroviruses. Flow cytometry. Flow cytometric analysis was undertaken using antibodies for mouse B220 (RA3-6B2), IgG 1 (X-56; Miltenyi Biotec), Fas (15A7), B7-1/CD80 (16-10-A1), IgM (II/ 41), CD138 (281-2), human CD4 (RPA-T4), and human CD8 (RPA-T8). Anti-mouse IgG 1 antibody (M1-14D12) was used as an isotype-matched control for anti-human CD4 antibody. Antibodies were purchased from eBioscience, except for X-56. Flow cytometric analysis was carried out using a FACSCalibur instrument (BD Biosciences, San Jose, CA, USA) and FlowJo software version 7.6.5 (Tree Star, Ashland, OR, USA).
Western blot analyses. Western blot analyses were carried out using anti-BCL6 (D-8; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CARD11 (#4440; Cell Signaling Technology, Danvers, MA, USA), anti-IRF4 (M-17; Santa Cruz Biotechnology), anti-PRDM1 (6D3; Santa Cruz Biotechnology), and anti-actin (AC-40; Sigma-Aldrich, St. Louis, MO, USA), anti-BCL2 (3F11; BD Pharmingen, San Diego, CA, USA), anti-a-tubulin (DM1A; Sigma-Aldrich), anti-Lamin B1 (L-5; Thermo Fisher Scientific, Rockford, IL, USA), anti-p65 (C-20; Santa Cruz Biotechnology) antibodies. Cytosolic and nuclear extracts were obtained using the Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA).
Analysis of cell clonality and SHM. To analyze the clonality and SHM of IGH genes in lymphoma cells, isolated genomic DNA was subjected to PCR using Ex Taq (Takara Bio) or KOD-plus2 (Toyobo, Osaka, Japan) along with primer sets that amplify the VDJ regions of IGH genes, as described previously. (29, 30) Combinations of forward (VHA, VHE, or VHG) and reverse (JH4 intron) primers were used. The resulting PCR products were gel-purified, cloned into the pCR4-TOPO vector (Invitrogen, Carlsbad, CA, USA), and sequenced. Every single plasmid was deemed to represent a distinct molecularly cloned sequence and, here, defined as a molecular clone. VDJ gene usage and somatic mutations were analyzed using IGBLAST (http://www.ncbi.nlm.nih.gov/igblast/). To determine the presence of intraclonal heterogeneity in lymphoma cells, confirmed mutations and unconfirmed mutations were defined as follows: (31) confirmed mutation, substitution mutations observed in more than one molecular clone sharing identical VDJ-rearranged sequence from the same tumor sample; unconfirmed mutation, substitution mutations observed in a single molecular clone from the same tumor sample. Only the confirmed mutations were used for the analysis of intraclonal heterogeneity, or ongoing SHM. The unconfirmed mutations were disregarded because they can be caused by PCR error. CARD11 mutant in lymphomagenesis, we reviewed published results of next generation sequencing of clinical samples, with special reference to those potentially enhancing the function of BCL6 or BCL2. (13) Of 12 lymphoma cases harboring CARD11 mutation, chromosomal translocations involving BCL6 and BCL2 existed in three and six cases, respectively, and mutations of CREBBP or MEF2B existed in two cases each (Fig. S1 ). The expression of BCL6 and BCL2 is under the control of heterotopic enhancer through chromosomal translocations. CREBBP mutant lost its ability to inactivate BCL6 by acetylation, (12) and MEF2B mutant can enhance BCL6 expression. (11) Notably, BCL6 translocations and mutations of CREBBP or MEF2B are mutually exclusive, suggesting that they collaborate with CARD11 mutant in a non-redundant manner in the development of lymphoma. Taken together, CARD11 mutations often co-exist with functionally enhanced BCL6 or BCL2.
Therefore, we first investigated the possible collaboration between CARD11 mutant, BCL6, and BCL2 in lymphoma development. To this end, we used iGCB cells as a target for the transduction of Card11 mutant, Bcl6, and Bcl2 genes, given that DLBCL originates in GC B cells. B220
+ murine B cells were isolated from the spleen of C57BL/6N mice, induced into GC B cells in culture, and retrovirally transduced with Card11 L232LI , Bcl6, and Bcl2. Mouse Card11 L232LI corresponds to the human CARD11 L225LI , an activating mutant. Card11 L232LI , Bcl6, and Bcl2 were programmed to co-express GFP and the extracellular domains of human CD4 and CD8, respectively, as surrogate markers enabling the identification of the transduced cells by flow cytometry (Fig. S3 ). Gene-transduced iGCB cells were then transplanted into immunodeficient mice, which were monitored for the development of lymphoma (Fig. S2 ). Experiments were independently carried out three times, using one (exp. 1), three (exp. 2), and two (exp. 3) mice, respectively. From a total of six mice transplanted with Card11 L232LI /Bcl6/Bcl2 triply transduced iGCB cells (referred to as "Card11 mut +Bcl6 + Bcl2 #1 to #6"), three mice were dissected while alive when disease signs (either tumor mass coupled with ascites or hepatomegaly) manifested (Card11 mut +Bcl6 + Bcl2 #1 to #3, Table S1 ). The remaining three mice were found dead, with two mice showing histologically evident lymphomas (Card11 mut +Bcl6 + Bcl2 #5 and #6); histological analysis could not be carried out on one mouse (Card11 mut +Bcl6 + Bcl2 #4). In total, five mice developed lymphomas and one died of unknown cause within 2 months of transplantation (Fig. 1a) . Mice that developed lymphomas manifested apparent tumor masses (Card11 mut +Bcl6 + Bcl2 #1 and #2) and/or hepatic involvement (Card11 mut +Bcl6 + Bcl2 #2, #3, #5, and #6), which were accompanied by infiltration of atypical lymphoid cells morphologically consistent with DLBCL (Fig. S4) .
To determine which of the three genes (Card11 L232LI , Bcl6, and Bcl2) contributed to the development of lymphomas in mice, we examined the expression of surrogate markers, GFP L232LI (GFP, green circles), Bcl6 (hCD4, blue circles), and Bcl2 (hCD8, yellow circles) before (upper panel) and after transplantation, on lymphoma development (lower panel). One (#1) and two (#2 and #3) mice developed lymphoma in two independent experiments. Percentages of cells co-expressing Card11 and Bcl6 are shown in red. The remaining three out six mice used in the experiment were found dead. Thus, viable cells were unavailable for flow cytometric analysis.
for CARD11 L232LI , hCD4 for Bcl6, and hCD8 for Bcl2, on the cells by flow cytometry. As viable tumor cells were only available from the three mice dissected while alive (see description above), our analysis was necessarily confined to them (Card11 mut +Bcl6 + Bcl2 #1-#3). Before transplantation, the percentages of cells expressing surrogate markers for the three transduced genes were variable and only a small fraction of the cells co-expressed hCD4 or hCD8 along with GFP. In contrast, almost all cells obtained from the developed lymphomas co-expressed both GFP and hCD4, with only a small fraction expressing hCD8, as exemplified in Card11 mut +Bcl6 + Bcl2 #1 (Fig. 1b) .
A similar analysis was conducted in Card11 mut +Bcl6 + Bcl2 #2 and #3 before (Fig. S5, exp. 2) and after lymphoma development (Fig. S6a) and the results are summarized using a Venn diagram (Fig. 1c) .
Tumorigenicity of Card11
L232LI and Bcl6 -transduced cells. We next tested if a combination of Card11 mutant and Bcl6 is sufficient for lymphoma development in separate experiments. Induced GCB cells were transduced with the two genes and transplanted. All mice (n = 11) developed lymphoma or died within 2 months of transplantation with rapidity and penetrance comparable with those of mice transplanted with cells transduced with Card11 L232LI , Bcl2, and Bcl6 (referred to as "Card11 mut +Bcl6 #1 to #11"; Fig. 2a , Table S1 ). Data were combined from four experiments carried out independently, using one (exp. 4), three (exp. 5), four (exp. 6), and three (exp. 7) mice. Seven mice were dissected while alive when disease signs manifested (Table S1 , Fig. S7 ) and tumor cells were isolated and analyzed by flow cytometry (Card11 mut +Bcl6 #1-#3, #5-#8; Figs. 2a, S6b) . Of the remaining four mice dissected after death, one had histologically evident lymphoma (Card11 mut +Bcl6 #11; Fig. S4 ) and one had no histologically detectable tumor (Card11 mut +Bcl6 #10). Detailed analysis could not be undertaken on the remaining two mice (Card11 mut +Bcl6 #4 and #9). Flow cytometric analysis revealed that Card11 L232LI -transduced cells always constituted the major component of lymphomas (Fig. 2a ), although the protein expression level of CARD11 was variable (Fig. 2b) between developed lymphoma cells. In contrast, the proportion of Bcl6-transduced cells in the developed lymphomas varied between developed lymphomas. Only a small fraction of cells co-expressed both Card11 L232LI and Bcl6 before transplantation. Cells co-expressing Card11 L232LI and Bcl6 became dominant in four of seven mice (Card11 mut +Bcl6 #1, #2, #5, and #6) (Fig. 2a) . These findings suggest that exogenously transduced Card11 L232LI and Bcl6 synergistically induced lymphomas in these mice, as was the case in mice transplanted with Card11 L232LI /Bcl6/Bcl2 transduced cells. Nevertheless, in the remaining three mice (Card11 mut +Bcl6 #3, #7, and #8), lymphomas mainly consisted of cells expressing only the surrogate marker for Card11 L232LI , suggesting that Bcl6 was not required for the development of these lymphomas. However, Western blot analysis revealed that, in two lymphomas (Card11 mut +Bcl6 #3 and #7), endogenous BCL6 was expressed at a level comparable to those of lymphoma cells expressing the exogenous Bcl6 gene with its surrogate marker and in a human GCB-DLBCL cell line, OCI-Ly8, which harbors BCL6 rearrangement (Fig. 2c) . (32) This finding implies that endogenous BCL6 was somehow upregulated, or rare clones with high endogenous BCL6 expression were selected during the course of lymphoma development in these recipient mice. Taken together, these findings suggest that Card11 mutant collaborates with exogenous or endogenous Bcl6 for the development of lymphoma.
Interestingly, in one (Card11 mut +Bcl6 #8) of seven mice, BCL6 was undetectable in lymphoma cells (Fig. 2c) , raising the possibility that transduced Card11 L232LI might induce lymphoma without the help of BCL6 in a limited number of cases. Indeed, in separate experiments using five mice transplanted with Card11 L232LI singly transduced cells, although lymphoma developed, the onset was significantly (P = 1.6 9 10 À3 ) delayed and the penetrance was lower than that in mice transplanted with Card11 L232LI /Bcl6 co-transduced cells. Only two of five mice receiving Card11 L232LI singly transduced cells developed lymphoma (referred to as "Card11 mut #1 and #2") ( Fig. 3; see also Fig. S6c, Table S1 ). We therefore do not exclude the possibility that Card11 mutant is able to induce lymphoma by itself, but our results clearly show that Bcl6 facilitates Card11-mediated lymphomagenesis. Three mice receiving Bcl6 only transduced iGCB cells died of unknown reasons (n = 1; 123 days after transplantation) or had no detectable lymphoma when killed (n = 2; 132 and 141 days after transplantation), suggesting that BCL6 alone is insufficient to induce lymphoma.
Clonality and properties of lymphomas developed in mice. We next analyzed the clonality of lymphomas. The VDJ regions of IGH genes were PCR amplified, cloned into plasmids, and sequenced. The results revealed that these tumors were oligoclonal (Card11 mut +Bcl6 #1) or monoclonal (Card11 mut +Bcl6 #2 and #3) (Fig. 4a) , suggesting that additional genetic or epigenetic factors, in addition to transduced genes, were needed for the development of lymphoma in our mouse model. Card11 mut +Bcl6 #2 and #3 lymphoma had only one VDJ rearranged sequence without confirmed mutations through analysis of multiple plasmid clones, whereas Card11 mut +Bcl6 #1 showed three distinct VDJ rearrangements, namely (IGHV1-26*01, IGHD1-1*01, IGHJ2*01), (IGHV1-26*01, IGHD2-3*01, IGHJ3*01), and (IGHV1-80*01, IGHD1-1*01, IGHJ3*02) (Table S2 ). Among these, only molecular clones using (V: 1-26*01, D: 2-3*01, J: 3*01) presented confirmed mutations, while the others did not. Ten molecular clones using (V: 1-26*01, D: 2-3*01, J: 3*01) presented identical confirmed mutations with no evidence of occurrence of ongoing SHM. The confirmed mutations were unlikely to be induced by PCR error, as they were identified in two independent experiments using different enzymes (Ex Taq and KODplus2). These findings indicate that, in our model, lymphomas lacked ongoing SHM.
The tumor cells were positive for B220 (a pan-B-cell marker), (33) IgM, and B7-1 (an activated B-cell marker) (Fig. 4b) . (34) They also expressed GC markers such as Fas, (35) although the expression levels were variable between lymphomas. Intriguingly, these tumor cells also expressed CD138 (a plasma cell marker), albeit weakly, and PRDM1 (a plasma cell differentiating transcription factor), suggesting that they differentiated toward plasmablasts (Fig. 4c) . (36) Both IRF4 (Fig. 4d) and BCL2 (Fig. S8) , known transcriptional targets of the NF-jB pathway, were highly expressed, consistent with nuclear translocation of p65 (RelA) that shows NF-jB activation (Fig. S9) . Together with high expression of FOXP1 (Fig. 4e) , a widely used classifier of ABC-DLBCL in humans, (37) these findings show that lymphoma cells developed in mice are consistent with DLBCL. Notably, all four secondary recipient mice transplanted with lymphoma cells derived from the primarily transplanted mice rapidly developed lymphoma within 20 days (Fig. S10) , indicating the tumor-propagating activity of the lymphomas; therefore, they are bona fide tumors.
Discussion
In this study, we showed the synergistic activity of Card11 L232LI and Bcl6 in lymphomagenesis in a mouse model. Evidence supporting the synergy between the two genes in the L232LI (red line) or Bcl6 alone (black line). An event is defined as the presence of lymphoma on dissection or death. The probability of event-free survival was compared with that of mice transplanted with cells transduced with Card11 L232LI and Bcl6 (dashed line). The difference in the probability of event-free survival was statistically significant (P = 1.17 9 10 À4 ), as determined by the logrank test. Post-hoc pairwise comparison was undertaken using Bonferroni correction. All P-values <0.05 are shown in the figure. development of lymphoma are threefold: (i) iGCB cells doubly transduced with Card11 L232LI and Bcl6 grew selectively over singly transduced cells in 7 out of 10 mice receiving cells transduced with Card11 L232LI /Bcl6/Bcl2 (n = 3, Fig. 1c ) or Card11 L232LI /Bcl6 (n = 4, Fig. 2a ) and these mice rapidly succumbed to lymphoma; (ii) although some lymphomas (in two of the remaining three mice) did not express the surrogate marker of exogenously transduced Bcl6, the expression of intrinsic BCL6 was elevated (Fig. 2c) ; and (iii) mice transplanted with cells transduced with Card11 L232LI and Bcl6 developed lymphoma with significantly higher incidence and shorter latency than those transplanted with cells transduced with either one of the genes (Fig. 3) .
Although synergistic, a combination of Card11 mutant and Bcl6 seems insufficient for lymphoma development, based on the following observations. First, lymphomas developed in mice that had oligoclonal or monoclonal IGH rearrangements, suggesting that not every single clone but a small number of clones contributed to the development of lymphoma (Fig. 4a) . Second, our preliminary use of immunocompetent mice as recipients of Card11 L232LI /Bcl6 transduced iGCB cells reduced the incidence of lymphoma compared with immunodeficient mice. Although the reasons for the difference are not clear, evasion from immunosurveillance may facilitate lymphoma development, as suggested by the findings that clinical lymphomas often harbor mutations in immunosurveillance-associated genes. (38) Lymphomas developed in our model were consistent with ABC-DLBCL, among others, in that they expressed IRF4 (10, 39) and FOXP1, (37) molecular markers of ABC-DLBCL, and PRDM1, critically involved in post-GC B cell differentiation. (40, 41) They also showed evidence of NF-jB activation. (42) Lack of ongoing SHM, the hallmark of GCB-DLBCL (43) further supports the identity as ABC-DLBCL.
The mechanism by which Bcl6 and Card11 L232LI might collaborate in lymphomagenesis remains unclear. Mutant CARD11 forms a complex with BCL10 and MALT1 and activates the NF-jB pathway, independently of B-cell receptor stimulation. (44) Although Card11 L232LI activates NF-jB signaling as such, the active NF-jB signaling per se is insufficient for lymphoma development. Expression of constitutive active IKK2ca in GC B cells in mice activates NF-jB, leading to enhanced cell proliferation, however, at the same time, provokes differentiation into plasma cells, failing to induce lymphoma development. The constitutive activation of NF-jB and the blockade of terminal differentiation into plasma cells therefore appear to be required for the development of ABC-DLBCL. (45) The activated canonical NF-jB pathway phosphorylates p65, which translocates into the nucleus, resulting in transcription of its target genes, including IRF4, (41, 46) which, in turn, induces expression of PRDM1, (47, 48) a transcription factor, which triggers the terminal differentiation into plasma cells. PRDM1 also functions as a tumor suppressor gene, (6) as the encoded protein inhibits the survival and proliferation of B cells. (49) When combined with conditional knockout of Prdm1, IKK2ca expressed in GC B cells elicits ABC-DLBCL. (5) The fact that PRDM1 is biallelically inactivated in human DLBCL (6) supports the idea that complete, rather than partial repression of PRDM1 is required for malignant transformation of B cells. Given that BCL6 represses Prdm1 transcription in cell lines (50) and that BCL6 translocation and PRDM1 inactivation are almost mutually exclusive in human DLBCL cases, (6) expression of BCL6 is anticipated to collaborate with the NFjB signaling activated by CARD11 mutant in lymphomagenesis, but this possibility has not been tested in animal models. Thus, our study provides an experimental evidence for the collaboration of the two genes. Although functions of BCL6 are partially mediated by the repression of Prdm1, lymphoma cells in our mouse model expressed PRDM1, albeit at lower levels than a myeloma cell line, suggesting incompleteness of the BCL6-mediated suppression of PRDM1, in stark contrast with PRDM1 knockout mice that recapitulates the biallelic inactivation of PRDM1 in human DLBCL. (6) Therefore, our findings raise the possibility that BCL6 may have other functions besides repressing PRDM1. Mutant Card11 activates JNK, (27) in addition to the NF-jB pathway, increasing the amount of phosphorylated c-Jun. (51) BCL6 modulates the transcriptional activity of c-Jun through physical interaction, (52) which may represent an additional mechanism underlying the collaboration between CARD11 and BCL6. However, further studies are warranted to investigate the role of this pathway in the development of lymphoma.
Although exogenously expressed BCL2 was dispensable for lymphomagenesis in our model, endogenous BCL2 expression was elevated in lymphoma cells induced by co-transduction of Card11 L232LI and Bcl6. Given that activated NF-jB directly drives BCL2 expression, (53) (54) (55) elevated BCL2 expression in our lymphoma, even without exogenous Bcl2, may reflect NFjB activation owing to Card11 L232LI transduction. This may at least partly explain elevated BCL2 expression in some human ABC-DLBCL cases without BCL2 translocation. (15) Although some DLBCL cases harbor both CARD11 mutation and BCL2 translocation, the sequence of these two events are not always known. In contrast, the two events happened almost simultaneously when induced in our experiments.
A mouse model of lymphoma, in which a mutant CARD11 is expressed from the embryonic stage in entire B cell fractions, has recently been reported. However, the animals developed lymphoma-like disease very rapidly after birth and with 100% penetrance, (51) in contrast to the low incidence of lymphoma (only two out of five mice) in our mice transplanted with Card11 L232LI only transduced iGCB cells. The difference in penetrance and rapidity of lymphoma development may reflect the difference in fractions of B cells (pan-B cells vs GC B cells) and the developmental stage (embryonic vs adult) in which CARD11 is expressed. Human lymphomas usually develop in advanced age and, indeed, even in patients with germline CARD11 mutation, the development of monoclonal B-cell disease culminates only in their 50s, despite polyclonal B-cell lymphocytosis coupled with splenomegaly and follicular hyperplasia being observed during their childhood. (25, 56) Together, these findings support the notion that CARD11 mutant needs additional genetic abnormalities to induce lymphoma.
CARD11 mutations are prevalent in ABC-DLBCL, (1, 24) a subtype of DLBCL, with poor prognosis. (37, 57) Although ibrutinib, a Bruton tyrosine kinase inhibitor, is a promising drug for ABC-DLBCL, it is ineffective for ABC-DLBCL cases with CARD11 mutations, (58) emphasizing the need for the development of new drugs. Our mouse model may help elucidate the molecular mechanisms underlying the development of DLBCL with CARD11 mutations to develop effective therapeutic agents.
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